Skip to main content
. 2021 Feb 22;6(4):e141088. doi: 10.1172/jci.insight.141088

Figure 5. LAIV vaccination increases levels of antibody against influenza in serum and nasal wash, with impaired nasal production caused by S. pneumoniae colonization.

Figure 5

(A) IgG titers to influenza, measured by ELISA, in serum of LAIV (n = 36) and TIV (n = 36) vaccinated subjects at baseline (8 days prevaccination) and D24 (24 days after vaccination). (B) FC (D24/baseline) of paired IgG titers to influenza in serum following TIV or LAIV vaccination. TIV/Spn– (n = 20), TIV/Spn+ (n = 16), LAIV/Spn– (n = 18), and LAIV/Spn+ (n = 18). (C) IgA and (D) IgG titers against influenza measured by ELISA in nasal wash of TIV (n = 40) and LAIV (n = 80) vaccinated subjects at baseline (8 days before vaccination) and D24 (24 days after vaccination). (E) FC (D24/baseline) of paired IgA and (F) IgG titers against influenza in nasal wash following vaccination with TIV/Spn– (n = 21), TIV/Spn+ (n = 19), LAIV/Spn– (n = 37), and LAIV/Spn+ (n = 43). Medians with IQR are shown. *P < 0.05, ***P < 0.001, ****P < 0.0001 by Wilcoxon’s test for comparisons within the same group and by Mann-Whitney U test for comparisons between groups.